Target intelligence / Profile preview

Steroid 5 alpha-reductase type 2 (SRD5A2)

Target: SRD5A2
Molecular classification: Enzyme

Overview

Steroid 5 alpha-reductase type 2 (SRD5A2) is an enzyme that catalyzes the conversion of testosterone to dihydrotestosterone (DHT), a more potent androgen. It is highly expressed in androgen-sensitive tissues like the prostate and is crucial for male sexual development. Mutations in SRD5A2 can cause 5-alpha reductase deficiency, leading to ambiguous genitalia. It is also a therapeutic target in benign prostatic hyperplasia and male pattern baldness.

Mechanism of action

Inhibition of steroid 5-alpha reductase type 2, reducing DHT levels

Biological functions

Androgen metabolismSteroidogenesisBile acid biosynthesisCholesterol metabolism

Disease associations

5-alpha reductase deficiencyProstate cancer

Interacting drugs

Finasteride

Beyond the preview

Go deeper on Steroid 5 alpha-reductase type 2 (SRD5A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Steroid 5 alpha-reductase type 2 (SRD5A2).

Explore the full profile